Pharmaceutical Perspectives of Cancer Therapeutics

  • Yi Lu
  • Ram I. Mahato

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Ajit S. Narang, Divyakant S. Desai
    Pages 49-92
  3. Ho Lun Wong, Xiao Yu Wu, Reina Bendayan
    Pages 121-148
  4. Arun K. Rishi, Xinbo Zhang, Anil Wali
    Pages 149-188
  5. Kyung H. Choi, Michel M. Ouellette
    Pages 189-205
  6. Dongin Kim, You Han Bae
    Pages 207-243
  7. Christian Dohmen, Manfred Ogris
    Pages 269-295
  8. Hiroshi Harada, Masahiro Hiraoka
    Pages 297-319
  9. Zsuzsanna Tabi
    Pages 365-397
  10. Kun Cheng, Bin Qin
    Pages 399-440
  11. Guofeng Cheng, Michael Danquah, Ram I. Mahato
    Pages 441-474
  12. Matthew A. Tyler, Adam Quasar Sugihara, Ilya V. Ulasov, Maciej S. Lesniak
    Pages 475-519
  13. Zheng Rong Lu, Anagha Vaidya
    Pages 581-599
  14. Jian Yan, Weikuan Gu
    Pages 645-672
  15. Dineo Khabele, Derrick Beech
    Pages 673-683
  16. Back Matter
    Pages 685-693

About this book


Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. The complexity of cancer demands an integrated understanding from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic regimen. This book combines and merges the knowledge from these two aspects. Internationally acclaimed experts with a multi-disciplinary background, including scientists and clinicians from both academia and industries have contributed to this book to bridge the following areas between basic research and clinical application, pharmaceutical drug development processes and regulatory issues, drug design and delivery, laboratory and translational experimentation, marketing and postmarketing surveillance.

Main features of the book:

  • Anticancer drug development and regulatory processes.
  • Strategies to suppress tumor angiogenesis and metastasis, overcome multi-drug resistance in cancer, target telomerase and apoptosis pathways.
  • Therapeutic approaches to employ monoclonal antibody and cancer vaccines.
  • Introduction of new concepts such as cancer stem cells and new technologies such as nanobiotechnology, RNA interference, microRNA, and cancer cell gene profiling.
  • Use of lipids, polymers and peptides for drug delivery and targeting to cancer cells or specific organs.
  • Utilization of bioimaging and HIF-1 knockout animal models in cancer study.
  • Clinical trials designs and principles


angiogenesis apoptosis gene therapy imaging surgery

Editors and affiliations

  • Yi Lu
  • Ram I. Mahato

There are no affiliations available

Bibliographic information